Home
/

Bacteroidota Gut Microbiome Test

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Key takeaway:

The Bacteroidota Test measures levels of Bacteroidota bacteria in your gut microbiome to detect imbalances associated with digestion, inflammation, and metabolic health. Identifying atypical Bacteroidota profiles can help guide dietary or lifestyle changes that may reduce risk of chronic gut issues and related metabolic problems.

Read more →
Table of contents

Mapping Your Gut's Fiber-Processing Phylum

The bacteroidota test analyzes DNA from your stool to estimate the relative abundance of microbes within the Bacteroidota phylum—organisms like Bacteroides, Prevotella, and Alistipes that specialize in breaking down complex carbohydrates and producing short-chain fatty acids. Modern sequencing approaches such as 16S rRNA profiling or whole-metagenome sequencing identify these microbes by their genetic signatures and compare your proportions to reference populations. Most results are reported as percentages rather than absolute counts, reflecting your current ecosystem balance rather than a permanent trait.

Why that matters: Bacteroidota help harvest energy from plant fibers, shape bile acid metabolism, produce compounds like acetate and propionate, and train the immune system at the gut lining. These activities influence digestion, inflammation, and metabolic signaling through the gut–brain and gut–liver axes. While microbiome science is evolving, consistent patterns emerge: stable diversity, adequate fiber-degrading capacity, and balanced representation of beneficial groups correlate with gut resilience. The bacteroidota test provides a focused window into that machinery.

What This Phylum Signals About Gut Resilience

Real life example: imagine two breakfasts—steel-cut oats versus a sugar pastry. Bacteroidota-rich communities are built to digest the long-chain fibers in the oats, releasing short-chain fatty acids that help maintain the gut barrier and signal to muscle and liver about glucose use. When this group is markedly low or skewed, people may notice more gas with high-fiber foods, variable stools, or harder-to-predict post-meal energy. Testing helps identify dysbiosis patterns linked to symptoms, flags potential impacts from recent antibiotics or restrictive dieting, and clarifies how your current eating pattern is interacting with your microbes. It is especially useful after major diet shifts, persistent GI symptoms, or recent infections when you want to understand how your gut ecosystem is recovering.

Zooming out, the gut microbiome influences glucose regulation, lipid handling, inflammation, and even how your body feels during workout recovery by modulating immune signals. Longitudinal microbiome testing lets you see how adjustments—like increasing fermentable fibers or managing stress—are reflected in microbial diversity and function over time. The goal is not a “perfect” number but pattern recognition. You learn how your microbial community behaves, then collaborate with your care team to support digestion, energy, and long-term health—without chasing trends that outpace the evidence.

Interpreting Your Bacteroidota Percentage

Your report typically shows the percentage of Bacteroidota compared with other major phyla and may highlight key genera (for example, Bacteroides or Prevotella) against a reference range from healthy populations. In general, a balanced microbiome shows higher overall diversity and a reasonable presence of fiber-degrading bacteria. Dominance by a single group or unusually low representation can signal imbalance, but context is crucial: diet, geography, and culture all shape what “normal” looks like.

What “balanced” suggests: efficient breakdown of complex carbohydrates; robust short-chain fatty acid production (notably acetate and propionate) that supports gut barrier integrity; and a steadier inflammatory tone. People with balanced patterns often report more predictable digestion and less reactivity to fiber-rich foods, though individual responses vary widely.

What “dysbiotic” may indicate: reduced diversity; a loss of beneficial fiber-degraders; or a tilt toward species linked to inflammation. Because Bacteroidota are gram-negative, their cell-wall components can interact with immune pathways—yet many members provide net benefits by fermenting fibers and producing metabolites that calm inflammation. An out-of-range result is a flag for exploration rather than a diagnosis. It points to functional patterns that may respond to dietary fiber variety, stress reduction, and, if symptoms persist, medical evaluation.

Variables That Shift the Number Without Telling You Much

Important limitations: stool testing captures what’s shed, not every microbe on the intestinal wall; results are relative proportions, which can shift with short-term diet changes or bowel habits; different labs and methods (16S vs. metagenomics) yield slightly different estimates; recent colonoscopy prep, antibiotics, or acute gastroenteritis can temporarily distort findings. That is why trends over time, plus your history and symptoms, tell the most useful story.

Big picture: microbiome data gain power when viewed alongside other biomarkers. Pairing bacteroidota test results with stool inflammation markers, metabolic labs, or even dietary logs can help your clinician triangulate the “why” behind your digestion and energy patterns. Think of this test as a map of your gut’s fiber-processing engine—valuable on its own, and even better when integrated into your broader health dashboard.

FAQs

The Bacteroidota Test analyzes the genetic material of bacteria, fungi, and other microorganisms in a stool sample to identify which species are present, their relative abundance, overall species diversity, and the functional potential encoded by microbial genes (e.g., metabolic pathways and gene families).

Results describe the microbiome’s composition and balance (which organisms are dominant or depleted and what functions they may perform) and are intended to inform about microbial ecology; they do not, by themselves, diagnose a specific disease or confirm clinical illness.

A Bacteroidota sample is collected at home using a simple stool collection included in the kit — typically a small swab for a tiny sample or a vial to capture a small amount of stool; the kit provides all materials and a clear step‑by‑step guide. You collect the sample per the kit instructions, secure it in the provided container, and prepare it for return shipping as directed.

Maintain good hygiene during collection (wash hands before and after), label the sample clearly with the required information, seal the container tightly, and follow the kit’s timing and storage instructions exactly — these steps are essential to prevent contamination and ensure accurate sequencing results.

Bacteroidota test results describe the relative abundance and diversity of Bacteroidota bacteria in your gut and can offer clues about several biological functions: digestion (how well complex carbohydrates and fiber are broken down), inflammation (microbial shifts that may be linked to higher or lower inflammatory signaling), nutrient absorption (effects on vitamin and mineral availability), metabolism (associations with energy balance and metabolic markers), and gut–brain communication (microbial metabolites that influence mood, appetite, and cognitive signaling).

These results can suggest patterns that are associated with certain health states, but microbiome patterns can correlate with, but don’t diagnose, specific health conditions; they are one piece of information best interpreted alongside symptoms, clinical tests, and a healthcare professional’s assessment.

Next‑generation sequencing (NGS) used in Bacteroidota tests provides high‑resolution microbial data and can detect and quantify bacterial DNA at species or strain levels, but interpretation is inherently probabilistic—results give estimates of relative abundance and associations rather than absolute diagnoses, and accuracy depends on sample quality, sequencing depth, and bioinformatic methods.

Results reflect a snapshot in time and may vary with recent changes in diet, stress, or antibiotic use, so findings should be interpreted in context and, when needed, confirmed or monitored over time.

Many people test their bacteroidota once per year to establish a baseline, and more frequently—about every 3–6 months—when actively adjusting diet, probiotics, medications, or other interventions to see how the community responds.

It’s more valuable to compare trends over time than to rely on a single reading: look for consistent directional changes across repeated tests rather than overinterpreting one-off fluctuations, and try to use the same sampling method and lab when possible so results are comparable.

Yes — microbial populations, including bacteroidota, can shift within days in response to diet, medications, travel, sleep or other lifestyle changes, but day-to-day variability is common and more stable community patterns typically emerge over weeks to months as the microbiome adapts.

For meaningful comparisons, try to keep diet and lifestyle consistent for several weeks before retesting so observed differences reflect true shifts rather than short-term fluctuations.

References

  1. El Kaoutari, A., Armougom, F., Gordon, J. I., Raoult, D., & Henrissat, B. (2013). The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nature Reviews Microbiology, 11(7), 497-504. https://doi.org/10.1038/nrmicro3050
  2. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041
  3. Durazzi, F., Sala, C., Castellani, G., Manfreda, G., Remondini, D., & De Cesare, A. (2021). Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. Scientific Reports, 11, 3030. https://doi.org/10.1038/s41598-021-82726-y
  4. Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. The New England Journal of Medicine, 375(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266
  5. Porcari, S., Mullish, B. H., Asnicar, F., Ng, S. C., Zhao, L., Hansen, R., O'Toole, P. W., Raes, J., Hold, G., Putignani, L., Gasbarrini, A., Segata, N., & Cammarota, G. (2025). International consensus statement on microbiome testing in clinical practice. The Lancet Gastroenterology & Hepatology, 10(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey